Skip to main content

Advertisement

Table 1 Correlation of Aurora B mRNA expression with clinicopathologic and molecular features in 160 patients with primary unifocal HCC by univariate logistic regression analyses

From: Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC

Feature Aurora B overexpression
  Total n (%) OR (95% CI)* P value
Age     
   > 55 88 49 (56) 1.0  
   ≤55 72 49 (68) 1.7 (0.89-3.25) 0.11
Gender     
   Female 38 23 (61) 1.0  
   Male 122 75 (61) 1.04 (0.49-2.19) 0.916
HBsAg     
   Negative 53 27 (51) 1.0  
   Positive 107 71 (66) 1.9 (0.97-3.72) 0.06
Anti-HCV     
   Negative 100 68 (68) 1.0  
   Positive 53 30 (57) 0.8 (0.41-1.57) 0.517
AFP     
   < 200 80 33 (41) 1.0  
   ≥200 80 65 (81) 6.17 (3.01-12.63) < 0.0001
Child-Pugh     
   A 147 93 (63) 1.0  
   B 11 5 (45) 0.48 (0.14-1.66) 0.24
Cirrhosis     
   No 99 66 (67) 1.0  
   Yes 61 32 (52) 0.55 (0.29-1.06) 0.073
Size (cm)     
   ≤5 72 37 (51) 1.0  
   > 5 88 61 (69) 2.14 (1.12-4.08) 0.021
Grade     
   I 31 10 (32) 1.0  
   II 74 48 (65) 3.88 (1.59-9.46)  
   III-IV 55 40 (73) 5.6 (2.15-14.61) 0.0007
Stage     
   I-II 66 21 (32) 1.0  
   IIIA-IV 94 77 (82) 9.71 (4.64-20.3) < 0.0001
ETR†     
   No 76 28 (37) 1.0  
   Yes 73 61 (84) 8.71 (4.02-18.91) < 0.0001
5-year survival     
   Yes 56 22 (39) 1.0  
   No 104 76 (73) 4.19 (2.11-8.36) < 0.0001
Aurora A overexpression     
   No 60 26 (43) 1.0  
   Yes 100 72 (72) 3.36 (1.72-6.58) 0.0003
p53 mutation     
   No 68 34 (50) 1.0  
   Yes 66 50 (76) 3.13 (1.5-6.53) 0.002
β-catenin mutation     
   No 128 85 (66) 1.0  
   Yes 22 7 (32) 0.24 (0.09-0.62) 0.002
  1. *OR: odds ratio; CI: confidence interval
  2. †ETR: early tumor recurrence within 12 months after surgery